Key Highlights

  • 4.29 percent was the October 5, 2026 gain for Repligen (NASDAQ:RGEN), which closed at about USD 189.50, according to published market data, one day before it completed the BioLife Solutions acquisition.
  • USD 11.25 in cash plus 0.1442 Repligen shares is what each BioLife share received at closing on October 6, 2026, under the July 21, 2026 Merger agreement disclosed by Repligen (NASDAQ:RGEN).
  • USD 1.5 billion was the Enterprise value Repligen (NASDAQ:RGEN) cited at signing, funded from existing cash, with at least USD 20 million of year-one synergies and USD 30 million in year two targeted.
  • USD 38.58 per BioLife share is the implied value at the October 5 close, simple arithmetic on two published numbers, versus the USD 31.00 headline at signing for Repligen (NASDAQ:RGEN) paper.

The October 5 Move and the Closing

Published market data show Repligen (NASDAQ:RGEN) closing at about USD 189.50 on October 5, 2026, up 4.29 percent, with premarket trading on October 6 roughly flat. The stock had fallen 7.80 percent on October 1 and gained 2.52 percent on October 2. On October 6, 2026, the company filed an 8-K confirming that the two-step merger with BioLife Solutions had been completed under an agreement dated July 21, 2026. Each eligible BioLife share converted into USD 11.25 in cash and 0.1442 Repligen shares, with cash paid in place of fractional shares. BioLife common stock was Delisted from Nasdaq effective October 6. The registration statement had become effective on September 4, 2026. No same-day move for October 6 was verified.

Mechanism: Cash and Stock Consideration

BioLife's Equity is paid partly in cash and partly in newly issued Repligen stock, so the value BioLife holders receive moves with the Repligen share price. At the signing announcement the package was valued at USD 31.00 per share, a 24 percent premium to the 90-day Volume weighted average price. Using the October 5 close, simple arithmetic gives 11.25 plus 0.1442 times 189.50, or about USD 38.58. The cash portion came from Repligen's existing cash, and the company said it expected more than USD 300 million of pro forma cash afterward. Repligen also guided to accretion of at least 5 cents per share in year one and 25 cents in year two.

Risks, Peers and What to Watch

BioLife supplies CryoStor biopreservation media used in 18 approved cell therapies, so Repligen (NASDAQ:RGEN) is adding exposure to a market that depends on funding, trial timing and regulatory outcomes. Integration risk, customer overlap and the share issuance are the main uncertainties, and the synergy targets remain company estimates. At signing, BioLife's preliminary second-quarter Revenue was USD 28.5 million, up 21 percent. Repligen said it would detail the financial impact on its third-quarter 2026 earnings call, with date not confirmed in the filings reviewed. Deferred financial statements and pro forma information are due within 71 days of the closing. Reported analyst moves include a JPMorgan price target of USD 175, which sits below the October 5 close.

Where Things Stand

Repligen (NASDAQ:RGEN) rose 4.29 percent on October 5, 2026 with no company announcement found to explain that single session; the BioLife deal closed the next day, October 6. Repligen now owns a high-margin cell therapy consumables franchise, paid for with cash and new shares. The 8-K gives no financing details beyond the merger terms. Investors will look to the third-quarter call for the first combined figures and for confirmation of the synergy and accretion targets.